Faculty

Faculty

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Appropriate Risk Assessment for Patients with Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence

• Clinicopathologic factors (eg, age, tumor size and grade, nodal involvement) affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer
• Long-term outcomes achieved with standard adjuvant endocrine therapy with or without chemotherapy for patients with HR-positive, HER2-negative localized breast cancer, including those at high risk for recurrence
• Mechanism of antitumor activity of CDK4/6 inhibitors; similarities and differences among available agents in this class
• Rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer

MODULE 2: Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer

• Extended follow-up, including recently published overall survival outcomes, with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
• Five-year outcomes with ribociclib and endocrine therapy compared to endocrine therapy alone as adjuvant treatment for high-risk, HR-positive, HER2-negative localized breast cancer
• FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib

MODULE 3: CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)

• Long-term follow-up data with abemaciclib, palbociclib and ribociclib for patients with HR-positive mBC
• Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
• Role of CDK4/6 inhibitors in treatment for unique patient populations, such as those with aggressive visceral disease and those with CNS metastases
• Available data on the utility of continuing CDK4/6 inhibitors beyond progression or rechallenge in later lines of therapy; current role of this strategy in clinical practice

MODULE 4: Cytopenias Associated with CDK4/6 Inhibitors

• Similarities and differences in the tolerability profiles of abemaciclib, palbociclib and ribociclib; spectrum and frequency of commonly occurring class-effect toxicities, such as cytopenias, gastrointestinal (GI) events and fatigue
• Appropriate monitoring of complete blood counts during CDK4/6 inhibitor therapy
• Thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias on CDK4/6 inhibitor therapy

MODULE 5: GI Adverse Events Documented with CDK4/6 Inhibitors

• Rates of various GI issues (eg, diarrhea, nausea and vomiting, constipation, abdominal pain) in patients receiving CDK4/6 inhibitor therapy
• Indications for antidiarrheals and/or antiemetics for patients receiving CDK4/6 inhibitors
• Role of nutritional counselling and diet modifications in CDK4/6 inhibitor treatment

MODULE 6: Rarer but Potentially Serious Toxicities Associated with 1 or More CDK4/6 Inhibitors

• Incidence of interstitial lung disease/pneumonitis associated with CDK4/6 inhibitor therapy; recommended algorithms for monitoring, mitigation and management
• Frequency and severity of hepatotoxicity documented with CDK4/6 inhibitors; appropriate monitoring of liver function tests before and during treatment
• Rates of venous thromboembolic events (VTE) reported with CDK4/6 inhibitor therapy; optimal monitoring for signs of VTE and precautionary measures for patients with preexisting risk factors
• Severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms) documented with CDK4/6 inhibitors; role of dermatologic consultation in the care of patients with signs or symptoms
• Incidence of cardiac toxicity with ribociclib; appropriate use of electrocardiogram monitoring before and during therapy

MODULE 7: Practical Considerations with CDK4/6 Inhibitors

• Optimal dosing and dose-adjustment strategies with CDK4/6 inhibitors for patients with localized and metastatic breast cancer
• Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
• Approaches for encouraging and assessing adherence for patients receiving CDK4/6 inhibitor therapy
• Drug-drug interactions noted with 1 or more CDK4/6 inhibitors

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
• Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
• Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
• Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
• Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Lilly and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Reva Basho

MD

Ellison Medical Institute, Los Angeles, California

Breast Medical Oncology, Chief Medical Officer

Faculty

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Faculty

Melissa Rikal

FNP-BC, AOCNP

Sarah Cannon Research Institute, Nashville, Tennessee

Nurse Practitioner

Moderator

Seth Wander

MD, PhD

Massachusetts General Hospital, Boston, Massachusetts

Director of Precision Medicine, Termeer Center for Targeted Therapies, Director of Translational Research, Breast Oncology Program

Harvard Medical School, Boston, Massachusetts

Assistant Professor of Medicine

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Identification of Appropriate Candidates with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway

• Incidence of relevant biomarkers, including alterations along the PI3K/AKT/mTOR pathway, in HR-positive, HER2-negative mBC
• Clinical characteristics associated with PI3K/AKT/mTOR pathway alterations in HR-positive, HER2-negative mBC
• Optimal methodology for and timing of assessment for alterations along the PI3K/AKT/mTOR pathway for HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating biomarker testing for HR-positive, HER2-negative mBC and helping patients understand the implications of the results

MODULE 2: Role of Inavolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between inavolisib and earlier-generation PI3K inhibitors (ie, alpelisib); implications for efficacy and tolerability
• Key findings with inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative mBC
• FDA approval of inavolisib/palbociclib/fulvestrant, and current clinical role for newly diagnosed HR-positive, HER2-negative mBC with a PIK3CA mutation
• Ongoing evaluation of inavolisib for endocrine-sensitive, PIK3CA-mutated, HR-positive, HER2-negative mBC; potential role in this setting

MODULE 3: Adverse Events (AEs) Associated with Inavolisib

• Incidence of hyperglycemia with inavolisib; optimal monitoring of fasting glucose levels and HbA1c
• Appropriate management of hyperglycemia occurring with inavolisib; indications for antidiabetic medications and dose modifications
• Incidence of gastrointestinal (GI) toxicities (eg, diarrhea, stomatitis, nausea) with inavolisib; strategies for mitigation and management
• Spectrum, frequency, severity and management of other toxicities (eg, cytopenias, fatigue, rash) documented with inavolisib-containing therapy

MODULE 4: Clinical Utility of Capivasertib in the Management of HR-Positive mBC

• Biological rationale for inhibiting AKT in the management of HR-positive mBC; mechanism of action of capivasertib
• Key efficacy and safety data with capivasertib/fulvestrant for recurrent HR-positive, HER2-negative mBC
• FDA approval of capivasertib for patients with HR-positive, HER2-negative mBC with PIK3CA/AKT1/PTEN alterations, and current role opposite other evidence-based options
• Ongoing evaluation of the triplet combination of capivasertib, fulvestrant and a CDK4/6 inhibitor as first-line therapy for patients with HR-positive, HER2-negative mBC who experience disease progression on or within 12 months of completing (neo)adjuvant endocrine therapy

MODULE 5: Side Effects and Other Practical Considerations with Capivasertib

• Recommended management strategies for patients experiencing diarrhea and other GI disorders while receiving capivasertib
• Pathophysiology, spectrum and optimal treatment of cutaneous adverse reactions with capivasertib
• Incidence of hyperglycemia in patients receiving capivasertib; indications for blood glucose monitoring and role, if any, for patients with preexisting diabetes
• Dose, schedule and recommended approach to dose modifications with capivasertib

MODULE 6: Potential Role of Gedatolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway for HR-positive mBC; implications for antitumor activity
• Recently presented data from the PIK3CA wild-type cohort of a Phase III study evaluating gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR-positive, HER2-negative mBC whose disease progressed on or after prior CDK4/6 inhibitor therapy and an aromatase inhibitor
• Anticipated read-out of the PIK3CA-mutated cohort of the aforementioned study
• Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated

MODULE 7: Tolerability Profile of Gedatolisib

• Rates of treatment discontinuation due to an AE documented with gedatolisib/palbociclib/fulvestrant and gedatolisib/fulvestrant
• Incidence and severity of hyperglycemia and diarrhea with gedatolisib-based therapy relative to other agents targeting the PI3K/AKT/mTOR pathway
• Spectrum and incidence of other treatment-related AEs documented with gedatolisib-based therapy (eg, stomatitis, neutropenia, nausea, vomiting, rash, fatigue)
• Strategies to monitor for, mitigate and manage treatment-related AEs with gedatolisib

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Review available research documenting the correlation between various biomarkers, such as PIK3CA/AKT1/PTEN alterations and ESR1 mutations, and response to specific therapies, and understand optimal testing algorithms for patients with hormone receptor (HR)-positive metastatic breast cancer (mBC).
• Recognize the frequency of PIK3CA/AKT/PTEN alterations in HR-positive mBC, and educate patients with newly diagnosed and relapsed/refractory disease about evidence-based approaches to targeting these aberrations.
• Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available and emerging data with this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
• Assess the spectrum, frequency and severity of adverse events associated with available and emerging agents targeting the PI3K/AKT/mTOR pathway, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Evaluate available research findings with and ongoing studies evaluating novel PI3K/AKT/mTOR inhibitor-based approaches, and consider the potential role of these strategies.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PI3KAKTmTORMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Basho — Advisory Committees: AstraZeneca Pharmaceuticals LP, Celcuity, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Scorpion Therapeutics; Data and Safety Monitoring Boards/Committees: Pfizer Inc; Speakers Bureaus: DAVA Oncology, MDOutlook; Nonrelevant Financial Relationships: Community Health Media, OncLive, Targeted Oncology. Ms Rikal — Advisory Committees: Stemline Therapeutics Inc; Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. Additional faculty to be announced.

MODERATOR — Dr Wander — Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio Inc, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, and Genentech, a member of the Roche Group.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.